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Abstract.   Cucumber mosaic virus (CMV) is a serious pathogen of  many economically important commercial fruit and
vegetable crops worldwide. It is a particular problem in warmer climates, where plants are not grown under cover thus
necessitating undesirably high use of  agrochemicals for the control of  insect vectors. Efforts towards controlling of  this virus
would include the development of  improved methods of  virus detection including the ability to produce cost effective and
specific reagents.  In this study the production of  recombinant antibodies provides one such approach.  A single chain variable
fragment (scFv) antibody, targeted to CMV coat protein, was constructed with mRNA from the spleen of  a CMV coat
protein-immunized mouse. The nucleotide sequence of  the variable heavy (VH) and variable light (VL) framework regions of
the mouse spleen cDNA were used to design and construct primers for scFv library construction via RT-PCR.  Three rounds
of  panning of  the scFv library with the coat protein of  a local isolate of  a chilli strain CMV resulted in the cloning of  a novel
soluble Flag-tagged scFv antibody that suitable for use as a diagnostic reagent with the further potential of  in situ application
in the development of  transgenic plants with novel resistance.
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INTRODUCTION
Cucumber mosaic virus is the type member of  cucumovirus
group, first discovered in Cucumis sativas in the USA
(Doolittle, 1916; Jagger, 1916). It is single-stranded RNA
virus and exists as a number of  allied strains. The virus
particle is isometric, not enveloped and 30 nm in diameter
(Kaper and Waterworth, 1981). The virus can be transmitted
by mechanical inoculation as in nature, by a number of
vectors commonly aphids (Smith, 1972). It infects forages,
cereals, woody and herbaceous ornamentals, vegetables, fruit
crops and other important agriculture crops. Systemic mosaic
is the typical symptom exhibited in most of the infected
plants (Kaper and Waterworth, 1981).
A cucumber mosaic virus (CMV) was identified in chilli
plants in Malaysia. The viral coat protein gene of  the virus
was amplified using RT-PCR and cloned into a bacterial
expression vector CP.pRSET. DNA sequence analysis of
the cloned fragment exhibited ≈93% similarity to published
CMV coat protein nucleotide sequence and ≈78% in terms
of  amino acid sequence (Tan, et al., 1998). The recombinant
CMV coat protein from the CP.pRSET construct was used
as the immunizing antigen in this study.
Generation of  single-chain variable fragments (scFv)
is now an established technique used to produce soluble
antibody in bacterial systems. An artificial peptide linker is
used to join the variable heavy (VH) and variable light (VL)
regions of  an antibody molecule to form the scFv which
has antigen recognition and binding affinity (Bird, et al., 1988;
Hutson et al., 1988). The scFvs are mainly constructed from
either hybridoma (Hutson et al., 1988) or spleen cells of
immunized mice (Clackson et al., 1991). The phage display
technique takes advantage of  the unique features of  the M13
phage life cycle as the scFv can be easily displayed as a fusion
protein on the minor coat protein (PIII) of  the fd phage
(McCafferty et al., 1990). In this study an anti-CMV scFv
was constructed via a bacteriophage system using purified
recombinant CMV coat protein as the immunizing antigen
antigen.
MATERIALS AND METHODS
Antigen preparation and mouse immunization.   E. coli
containing the plasmid CP.pRSET harbouring the CMV coat
protein was induced overnight with 0.3mM isopropyl-β-D-
thiogalactopyranoside (IPTG) and the expressed coat protein
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was subjected to column purification under native conditions
using Xpress® Protein Purification System (Invitrogen).
Bacterial cells were harvested by centrifugation at 3000 x g
for 15 min and the expressed protein purified following
manufacturer’s instructions. One mg/ ml of  the purified
CMV coat protein was emulsified with Freunds adjuvant
(Sigma) and injected into a Balb/c mouse through the
subcutaneous route. Booster injections were carried out using
incomplete adjuvant three times at 2-week intervals. Four
days after the final injection, the mouse serum was tested by
enzyme-linked immunosorbent assay (ELISA) to confirm
the presence of  anti-CMV antibodies prior to removal of
the spleen for the subsequent procedures.
Amplification of  the variable heavy (VH) and variable
light (VL) chains and construction of  single chain
variable fragment (scFv).   Total RNA was extracted from
the spleen cells of  the immunized mice using the RNeasy
Mini Kit (QIAGEN, USA) followed by mRNA purification
using an Oligotex™ Kit (QIAGEN, USA). First strand
cDNA was synthesised from the mRNA. This was followed
by amplification of  the VH and VL genes separately using
universal VH primer 1, VH primer 2 and VL primer mix
respectively (Amersham Pharmacia) at 94°C for 1 min, 55°C
for 2 min and 72°C for 2 min for 30 cycles) in a PCR
thermocycler (Eppendorf  5330). The PCR mix typically
contained Taq polymerase (Roche, USA) in standard buffer
mix. The amplified VH and VL DNA fragments were then
ligated separately into pGEM®-T easy vectors (Promega)
and transformed E. coli DH5α (supE44, hsdR17, recA1, endA1,
gyrA96, thi-1, relA1) with the construct. T7 (5'-TAA TAG
ACG ACT CAC TAT AGG G-3') and SP6 (5'-CTA TTT
AGG TGA CAC TAT AG-3') primers were used for PCR
screening of  inserted DNA in the putative transformants.
Positive clones carrying either the VH genes or VL genes
were randomly selected and the insert DNA amplified and
sequenced to determine the framework region sequence for
designing new primers. Based on the sequencing results
(Chua, 2002), 4 primers were designed (VHA and VHB are
forward and reverse primers for VH gene amplification and
VLA and VLB for VL gene amplification) (Table 1)
containing nonsense sequence, new restriction endonuclease
sites, a synthetic linker (Gly4Ser)3, Flag-tag sequences and
part of  the frame-work sequences. These primers were used
to amplify combinatorial VH and VL DNA fragments. The
VH and VL DNA fragments were cloned into the pCANTAB
5E vector through 3 fragment ligation. A schematic diagram
of  the full linking procedure is shown in Figure 1.
Transformation of  scFv construct and rescue of
recombinant phage.   The pCANTAB 5E plasmid carrying
the scFv construct was inserted into E. coli TG1 cells (K12
∆(lac-pro), supE, thi, hsd”5/F’ [traD36, proAB’ lacIq, lacZ∆M15])
through electroporation at 2.5 kV, 25 µF for 0.45 msec.
Transformed TG1 cells were recovered in 1 ml of  2X YT
medium (0.1% yeast extract, 1.7% tryptone, 0.05% sodium
chloride) with 2% glucose and incubated at 37°C with
shaking at 250 rpm for 1 hour. The transformed cells were
then plated on 10 SOBAG plates (0.002 w/v bacto-trypton,
0.005 w/v bacto-yeast extract, 0.008 M sodium chloride,
0.01 M magnesium chloride, 0.111 M glucose, 100µg/ ml
ampicillin) and incubated overnight at 37°C. On the
following day, plates containing colonies were flooded with
2X YT medium with 100 µg/ ml ampicillin and 2% glucose
(2X YT-AG) and transferred into a 50 ml polypropylene
tube (Falcon, USA). The culture mixture was diluted with
appropriate amount of  2X YT-AG medium until an O. D.
of  0.5 at A600. Two membranes were duplicated from a
culture plate for colony hybridisation experiments and PCR
detection was also carried out on randomly selected colonies
for the inserted scFv. To 10 ml of  the culture mixture,
approximately 4 x 1010 pfu of  the M13KO7 helper phage
was added and incubated at 37 °C with shaking at 250 rpm
for 1 hour.  Following that, the pellet was collected by
centrifugation at 1,000 x g for 10 min and resuspended in
10 ml of  2X YT medium containing 100 µg/ ml of  each
ampicillin and kanamycin. The culture was incubated at 37°C
with shaking at 250 rpm overnight, then centrifuged at
1,000 x g for 20 min after which 2 ml of  polyethylene glycol/
sodium chloride was added to the supernatant and incubated
on ice for 60 min. Centrifugation at 10,000 x g for 20 min at
4 °C was carried out and the supernatant was discarded.
The phage pellet was then resuspended in 2 ml of  2X YT
medium and used in subsequent biopanning experiments.
Colony hybridisation.   Colony hybridization was carried
out using VH or VL chain PCR amplified products as the
probes (3 µg/µl) which were labeled using the Digoxigenin
DNA Labeling and Detection Kit (Roche). The
Nitrocellulose membrane with colony DNA was prepared
as described in Sambrook et al., 1989.
Biopanning for Selection of  the Recombinant Phage
Expressing the Single-Chain Variable Fragment (scFv).
Wells of  sterile 96 wells ‘U’ bottom microtiter plates (Costar)
were coated with 10 µg purified and dialyzed virus coat
protein in 200 µl of 0.05 M sodium carbonate (pH 9.6) as
the antigen, sealed tight and incubated overnight at 4 °C.
On the following day, the antigen-coated well was washed 3
times using phosphate-buffered saline (PBS) and 200 µl of
blocking buffer (10% skim milk in PBS) was used to block
remaining wells then the plates were sealed and incubated
at 37 °C for 2 hours followed by 3 washes with PBS. Fifty
microliters of  the supernatant containing the recombinant
phage were added to the appropriate wells and incubated at
37 °C for 2 hours. The unbound phage was then removed
and the well was washed thoroughly with phosphate-buffered
saline- Tween 20 (PBS-T) at least 60 times.
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Primer 1: VHA 5'AAGGAAAAAAGGCCCAGCCGGCCATGGTSMARCTGCAGSAGTCWGCAMCTGA3'
Primer 2: VHB 5'CGGGCGGCGGTCCGGATCCACCTCCGCCTGAACCGCCTCCACCTGAGGAGACGGTGACCGTGGTCCCTTG3'
Primer 3: VLA 5'CGGGCGGCGGTCCGGAGGTGGCGGTTCGSAAAWTGTKCTCACCCAGTCTCCAGCAATC3'
Primer 4: VLB 5'AAGGAAAAAAGCGGCCGCGTCGAC[CTTGTCATCGTCGTCCTTGTAGTC]GACCCGTTTBAKYTCCAGCTTRG





Table 1.   Primers used for amplification of  variable heavy (VH) and light (VL) chains
Nonsense sequence is italicised. Sfi I site, BspE I sites and Not I site are given in bold and labeled accordingly. The start codon is boxed.
The synthetic peptide linker is underlined and the Flag-tag sequence is in marked with square brackets.
 Total RNA of mouse spleen cells 
 
 
mRNA of mouse spleen cells 
 
 







VHA    VHB    VLA    VLB 
 
(Start codon + VH + Part of the linker)   (Part of the linker + VL + Flag-tag) 
 





VH       VL 
 
Start codon         Flag-tag 
    Sfi I        Not I 
Figure 1.   Schematic diagram for the scFv construction. The diagram represents the scFv construction strategy. Explanation of  the
strategy is as in text. The diagram is not drawn to scale. VH - variable heavy chain of  an antibody; VL - variable light chain of  an antibody;
VHA and VLA - forward primers for amplification of  VH and VL genes respectively; VHB and VLB - reverse primers for amplification
of  VH and VL genes respectively; white boxes - part of  the linker; black box - Flag-tag sequence; ATG - start codon.
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Reinfection of  Escherichia coli with Recombinant
Phage.   To the well containing bound phage, 50 µl of
trypsin (10 mg/ ml) was added and incubated at 37 °C for
30 min. Vigorous pipetting was done and the trypsin solution
containing recombinant phage was used to infect 10 ml of
2X YT medium containing log phase TG1 cells. The culture
was incubated at 37 °C for 1 hour with 250 shaking. Prior to
second round of panning, 100 µg/ ml of ampicillin, 2%
glucose and 4x 1010 pfu of  M13KO7 were added to the
TG1 cell suspension and the procedures, as described
previously, repeated.
Immunodetection of  Positive Recombinant Phage.
The method used for immunodetection was based on the
protocol provided by RPAS (Amersham Pharmacia). CMV
coat protein (10 µg/ ml) in 200 µl of 0.05M sodium
carbonate (pH 9.6) was dispensed into 147 separate wells in
the microtiter plate. The plate was incubated overnight at
4 °C.  On the following day, the contents of  each well were
removed, 200 µl of  blocking buffer was added and the plate
was incubated at 37 °C for 2 hours. One hundred µl of  the
supernatant containing the scFv expressing recombinant
phage were added to the plates after the blocking buffer
was decanted. Two rows of  wells were incubated with
M13KO7 helper phage in blocking buffer as the negative
control. The plate was incubated at 37 °C for 2 hours and
then washed 3 times with PBS-T. Sheep anti-Ml3 IgG horse
radish peroxidase conjugate (Amersham Pharmacia) was
diluted 1:5000 in blocking buffer and 200 µl of  the solution
was added to all wells. The conjugates were incubated at
37 °C for 2 hours and washed as previously described.
Following the washing, 200 µl of  1X 2', 2'-azino-bis
(3ethylbenzthiazoline-6-sulphonic acid) diammonium
(ABTS) substrate containing 0.05% H202 was added to each
well and the plates incubated at room temperature for 20-
60 minutes until a suitable colour (green) appeared. The
absorbency was determined at 414 nm using a microplate
reader, Titertek Multiskan Mcc/340 P.
Soluble scFv antibody production.   The scFv clone with
the highest binding affinity was chosen and the construct
extracted though DNA mini-preparation then inserted into
competent E. coli strain HB2151 (K12 “(lac-pro), ara, nalr,
thi/F’[proAB, lacIq, lacZ∆M15]) through transformation
technique. The transformed E. coli HB2151 cells were plated
on SOBAG-N (0.02 w/v bacto-tryptone, 0.005 w/v bacto-
yeast extract, 0.0015 w/v bacto-agar, 0.0005 w/v sodium
chloride, 10 mM magnesium chloride, 0.1 M glucose, 100
µg/ ml ampicillin, 100 µg/ ml nalidixic acid) and incubated
overnight at 30 °C. Selected colonies of  E. coli HB2151 were
inoculated into 5 ml of Super broth medium (0.035 w/v
bacto-tryptone, 0.02 w/v bacto-yeast extract, 0.085 M
sodium chloride) containing 100 µg/ ml ampicillin and 2%
glucose (SB-AG) and incubated overnight at 30 °C with
shaking at 250 rpm. After incubation, 5 ml of  the overnight
culture was used to inoculate 10 ml of  SB-AG and incubated
at 30 °C for 4 hours with shaking at 250 rpm. After the
incubation, the bacterial pellet was collected from the culture
by centrifugation at 1500 x g and resuspended in Super broth
containing 100 µl/ ml ampicillin and 1 mM IPTG (SB-AI)
medium. Incubation was carried out overnight at 30°C and
shaking at 250 rpm.  After that, the bacterial pellet was
collected by centrifugation and resuspended in 0.5 ml of
ice-cold 1X TES buffer (0.2 M tris hydrocloride, 0.5 mM
ethylenediaminetetra-acetate acid, 0.5 M sucrose). A volume
of  0.75 ml of  ice-cold 1/5 X TES buffer was added and the
mixture vortexed then incubated on ice for one hour. Finally,
the supernatant containing scFv antibody from the bacterial
periplasm was collected by centrifugation at full speed. If
not used immediately, the antibody was stored at -20 °C
prior to use in immuno-detection experiments.
Western Blot and ELISA Detection.   Total protein of
E. coli containing scFv antibody was separated on 12%
sodium dodecyl sulphate-polyacrylamide gel electrophoresis
(SDS-PAGE) in denaturing buffer. Fractionated protein on
the gel was transferred to a nitrocellulose membrane using
a trans-blotter (Bio-Rad).  Blocking, incubating and washing
steps were performed as described in Sambrook et al., 1989.
The presence of  the soluble scFv antibody protein was
detected using anti-Flag M2 monoclonal antibody (Sigma)
and Fc specific goat anti-mouse IgG conjugated with
Horseradish peroxidase (HRP) (Pierce). The soluble protein,
which acts as a probe for western blot detection was added
to the membrane with unpurified total bacteria including
expressed CMV coat protein. Following that, anti-Flag and
lastly goat anti-mouse IgG-HRP was added for detection.
Direct ELISA detection using infected leaf samples and
unpurified expressed coat protein was carried out as
described by Michael et al., 1988.
Automated DNA sequencing.   Plasmid DNA was isolated
from the transformed E. coli using Qiagen Plasmid Miniprep
kit (QIAGEN) and subjected to cycle sequencing using
ABI377 (Perkin Elmer). The primers used for sequencing
were pCANTAB5-S1 (5'-CAA CGT GAA AAA ATT ATT
ATT CGC-3') as the forward primer and pCANTAB5-S6
(5'-GTA AAT GAA TTT TCT GTA TGA GG-3') as the
reverse primer.
RESULTS
The ≈35 kDa CMV coat protein used as the immunizing
antigen was successfully expressed (Figure 2) and verified
using anti-CMV polyclonal antibody as a probe. mRNA of
mouse spleen tissue was successfully extracted and an
approximate 427 bp VH chain DNA fragment and 402 bp
VL chain DNA fragment were obtained with primers VHA/
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VHB and VLA/ VLB respectively (Figure 3). The amplified
products contained additional sequences including nonsense
sequence, start codon (for VH), restriction sites, part of  the
linker sequence (for VH and VL) and Flag-tag sequence (for
VL). After restriction enzyme digestion, the VH and VL chain
amplified fragments were then ligated into pCANTAB 5E
which resulted in a pool of  3 x 108 independent scFv
recombinants. The presence of  the VH and VL chains in the
combinatorial library was determined by colony hybridisation
using DIG-labelled VH or VL probes with almost 100%
transformation recorded for each preparation. This was
further confirmed through PCR using primers VHA and
VHB on randomly selected transformed cells (Figure 4).
The expected 774 bp amplified fragment of  the scFv
indicated that the recombinant scFv was successfully
constructed and transformation of  E. coli strain TG1 with
the desired construct was done. After two rounds of
biopanning using ELISA plates coated with purified chilli
strain CMV coat protein as the antigen, 123 colonies were
selected. All of  the colonies were then picked for another
round of  the gene rescue and biopanning to select the scFv
clone with the highest affinity. The scFv clones which showed
the most significant absorbance ratio (≈3.46), had the highest
binding affinity, and were selected for soluble scFv
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Figure 2.   Western-blot immunodetection of  the expressed coat
protein from the CP. pRSET construct. Total protein obtained
from induced E. coli carrying CP.pRSET construct was
electrophoresed on a 12% SDS PAGE gel, transferred onto
nitrocellulose membrane (Protran) and detected using anti-CMV
polyclonal antibodies. Lane 1: kaleidoscope prestained protein
marker (Bio-Rad); lane 2-4: Products from samples. The position
of  the band migration at the predicted molecular weight (≈ 35




 ≈321 bp 
bp 
          1       2       3       4         5        6 
300 
≈356 bp ≈ 427 bp  ≈400 bp 
Figure 3.   Amplification of  the VH and VL chain genes using self-
designed primers. Amplification of  the VH and VL chain genes
was carried out using commercial and self-designed primers.
Samples were electrophoresed on a 1% agarose in 1X TBE buffer.
Lane 1: 100 bp DNA ladder (Gibco BRL); Lane 2: VH DNA
fragment amplified using VHA and VHB primers; Lane 3: VL DNA
fragment amplified using VLA and VLB primers; Lane 4: negative
control where PCR amplification using VHA and VHB primer
and distilled water as the template; Lane 5: VH DNA fragment
amplified using VH primer 1, VH primer 2 (Amersham Pharmacia);
Lane 6: VL DNA fragment amplified using VL primer mix
(Amersham Pharmacia).
signal for putative scFv protein (≈32 kDa) was detected using
anti-Flag monoclonal antibody in the induced HB2151
periplasmic samples carrying the selected scFv clones (Figure
5) after overnight incubation at 30 °C with agitation at 250
rpm. No band was observed in the uninduced sample
incubated under the same conditions. Detection of  the Flag
peptide, which was constructed at the carboxyl terminus of
the scFv, indicated that the scFv was successfully cloned
and expressed. Experiments using the soluble anti-CMV
scFv antibody as a probe for ELISA detection on sap extract
of infected leaf samples (A414= 0.819) and purified CMV
coat protein (A414= 0.511) showed a significant absorbance
ratio of  more than 2, whilst negative results were obtained
when the banana streak virus was used as the negative control
antigen (A414= 0.046). In Western blot experiments for
detection of the CMV coat protein, a 35 kDa CMV coat
protein was observed in the induced E. coli carrying CP.
pRSET construct, while no band was observed in the
uninduced E. coli (Figure 6). Nucleotide and the deduced
amino acid sequences of  the heavy and light chains are shown
in Figure 7.
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DISCUSSION
CMV infection affects many economically important plants
and is the major viral pathogen affecting chilli in Malaysia.
CMV has many isolates differing in their host range and
pathogenicity as documented by Kaper and Waterworth in
1981. The isolate used as the immunizing antigen in this
study was found in infected chilli plant in Malaysia. In this
study, construction of  a recombinant anti-CMV scFv as an
alternative source of  antibodies for use in CMV diagnostics
was successfully carried out. The production of  recombinant
antibody is, in the long term, a potentially cheaper and easier
approach for the production of  diagnostic reagents
compared to the current source of  such CMV antibodies
from animals or monoclonal cell lines.
In this study immunized mouse spleen tissue was used
to construct the scFv as the cells are a rich source of
immunoglobulin genes and repertories of  VH and VL genes
can be easily amplified from the mRNA of  such cells
(Hawkins et al., 1992). A time-saving one-step cloning
procedure modified form (Chee and Sazaly, 1998) was used
in the experiment to construct an scFv combinatorial library
prior to biopanning for selection of  the best scFv construct.
This method bypasses conventional two-step protocols using
an intermediate cloning vector and potentially minimizes
the possibility of  mutations associated with extended
protocols. The unique primers designed in this study enabled
easy linking of  the two chains and again bypassed the difficult
PCR assembly method described by Horton et. al., 1989.
As the frame-work regions of  VH and VL chain of  an
immunoglobulin are relatively conserved within an animal
species, sequence information could be obtained for both
chains. From our results, we found that other than the highly
conserved 3' end of  the VH chain framework region, some
of  the framework nucleotide sequences of  both chains were
not identical when the sequence from several clones was
compared. However, since there were differences in only a
few nucleotide sequences, degenerate primer design was still
possible. The additional nonsense sequence introduced at
the 5' end of  the primers was to increase the cleavage
efficiency of  the amplified VH and VL chain DNA fragments
by restriction endonucleases, and the additional tag sequence
at the carboxyl terminus of  the scFv was added to facilitate
the detection and purification in subsequent steps (Clackson
et al., 1991). In addition the construct contained an E-Tag
as a result of  cloning into the pCANTAB 5E vector, thus
allowing for both anti-E tag or Flag-tag detection in future
applications. To ensure production of  soluble antibodies,
the non-suppressor E. coli strain HB2151 was used without
any modification or manipulation of  the selected scFv. In
this E. coli strain, protein synthesis is aborted at the end of
the scFv gene due to recognition of  a stop codon and as a
result, the g3p fusion protein is not made and the scFv is
transported and accumulates in the periplasmic location of
the bacteria up to certain maximal level, after which the
soluble scFv antibody will leak into the medium
(Hoogenboom et al., 1991). We successfully obtained soluble
anti-CMV scFv antibody not only in the periplasmic extract
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Figure 4.   Detection of  scFv through PCR method. Nine colo-
nies were randomly chosen for PCR detection using VHA and
VLB primers. Lane 1: 10 bp DNA ladder (Gibco BRL); Lane 2-4
and 6-11: 774 bp bands were detected in all the samples; Lane 5:
Negative control where bacterial colony carrying pCANTAB 5E
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Figure 5.   Immunodetection of  the induced E. coli HB2151 car-
rying selected anti-CMV scFv construct. Transformed E. coli
HB2151 carrying anti-CMV scFv clones were induced with 0.5
mM of  IPTG and incubated at 37 °C for 4 hours. Total protein of
the bacterial periplasm was extracted and 2 µg of  the total pro-
teins were electrophoresed on a 12% SDS PAGE gel. Fractionated
proteins were then transferred onto a nitrocellulose membrane
and detected using anti-FLAG monoclonal antibodies followed
by Goat anti-mouse IgG-HRP. Lane 1: kaleidoscope prestained
protein marker (Bio-Rad), Lane 2, 4, 6, 8: uninduced samples; Lane:
3, 5, 7, 9: induced samples. The position of  the band migration at
the predicted molecular weight (≈32 kDa) of  the recombinant
scFv is indicated by the arrow.
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of  induced bacteria cells, but also from the culture medium
making larger scale purification potentially very simple.
This study showed that the recombinant scFv had
binding affinity to the immunizing antigen and can be
developed for detection of  chilli CMV infections. ScFvs have
been developed as specific diagnostic reagents against other
viruses including HIV (De Haard et al., 1998). However as
CMV is a highly heterogenous group we believe that a
combination of  specific scFvs or an scFv that would
recognize a shared epitope may be further isolated form the
library generated in this study and would then be applicable
as a general diagnostic reagent for the group. Other than
this ex situ application, further potential of  the recombinant
antibody fragment would be the development of  transgenic
plants with a novel in situ form of  resistance against the
targeted antigen (Tavladoraki et al., 1993; Whitelam and
Cockburn 1997). Initial studies using this approach (Chua,
2002) has shown promising results in tobacco plants with
the final aim of  producing CMV resistant chilli in the near
future.
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Figure 6.   Determination of  the binding affinity of  the selected
scFv antibody by Western  blot. CMV coat protein was separated
on a 12% SDS-PAGE gel and blotted to nitrocellulose membranes.
Detection was carried out using anti-CMV scFv antibody as the
primary antibody with anti-E HRP conjugate as the secondary
antibody followed by anti-Flag and Fc region specific goat anti-
mouse IgG-HRP conjugated antibody (Pierce). Lane 1:
kaleidoscope prestained protein marker (Bio-Rad); Lane 2: coat
protein of  the crude CMV coat protein extracted from the induced
bacteria carrying pRSET.CP construct; Lane 3: total protein of
the wild type E. coli. The position of  the band migration at the
predicted molecular weight (≈35 kDa) of  the CMV coat protein is
indicated by the arrow.
VH Chain Nucleotide Sequence 
 
GTG CAG CTG CAG GAG TCA GCA ACT GAG CTG GTG AAG CCT GGG GCT TCA GTG AAG ATA TCC  
 V   Q   L   Q   E   S   A   T   E   L   V   K   P   G   A   S   V   K   I   S  
                                 CDR-H1    
TGC AAG GCT TCT GGC TAC TCC TTC ATT GTC CAC TAT ATA AAC TGG GTG AAG CAG AAG CCT  
 C   K   A   S   G   Y   S   F   I   V   H   Y   I   N   W   V   K   Q   K   P   
                                                 CDR-H2 
GGA CAG GGA CTT GAG TGG ATT GGA TGC TTT TTT CCT GGA AGC GGT AAT AGT AAG TAC ATT  
 G   Q   G   L   E   W   I   G   C   F   F   P   G   S   G   N   S   K   Y   I   
 
GAG AAC TTC AGG GGC AAG GCC ACA TTG ACT GTA GAC ACA TCC TCC AGT ACA GCC TAC ATG  
 E   N   F   R   G   K   A   T   L   T   V   D   T   S   S   S   T   A   Y   M   
 
CAG CTC AGC AGC CTG ACA TCT GAG GAC ACT GCT GTC TAT TTC TGT GCA AGG GAT GAT TCC  
 Q   L   S   S   L   T   S   E   D   T   A   V   Y   F   C   A   R   D   D   S   
         CDR-H3 
GAC GGA GCT ATG GAC TAC TGG GGC CAA GGG ACC ACG GTC ACC GTC TCC TCA 
 D   G   A   M   D   Y   W   G   Q   G   T   T   V   T   V   S   S 
 
VL Chain Nucleotide Sequence 
 
GAA ATT GTT CTC ACC CAG TCT CCA GCA ATC ATG TCT GCA TCT CCA GGG GAG AGG GTC ACC 
 E   I   V   L   T   Q   S   P   A   I   M   S   A   S   P   G   E   R   V   T 
    CDR-L1 
ATG ACC TGC AGT GCC AGC TCA AGT ATA CGT TAC ATA TAT TGG TAC CAA CAG AAG CCT GGA  
 M   T   C   S   A   S   S   S   I   R   Y   I   Y   W   Y   Q   Q   K   P   G   
      CDR-L2 
TCC TCC CCC AGA CTC CTG ATT TAT GAC ACA TCC AAC GTG GCT CCT GGA GTC CCT TTT CGC  
 S   S   P   R   L   L   I   Y   D   T   S   N   V   A   P   G   V   P   F   R   
 
CTC AGT GGC AGT GGG TCT GGG ACC TCT TAT TCT CTC ACA ATC AAC CGA ACG GAG GCT GAG  
 L   S   G   S   G   S   G   T   S   Y   S   L   T   I   N   R   T   E   A   E   
      CDR-L3 
GAT GCT GCC ACT TAT TAC TGC CAG GAG TGG AGT GGT TAT CCG TAC ACG TTC GGA GGG GGC  
 D   A   A   T   Y   Y   C   Q   E   W   S   G   Y   P   Y   T   F   G   G   G   
     
ACC AAG CTG GAG CTC AAA CGG 
 T   K   L   E   L   K   R 
Figure 7.   Nucleotide and the deduced amino acid sequences of
the heavy and light chains. Complementarity determining regions
(CDRs) shown in boldface. Heavy chain VH (GenBank Acc. No.
AY 337618). Light chain VL (GenBank Acc. No. AY 337619)
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